WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017061828) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING INHIBITOR OF PLRG1 (PLEIOTROPIC REGULATOR 1) AS ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/061828 International Application No.: PCT/KR2016/011272
Publication Date: 13.04.2017 International Filing Date: 07.10.2016
IPC:
A61K 48/00 (2006.01) ,A61K 39/395 (2006.01)
Applicants: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES[KR/KR]; 75, Nowon-ro, Nowon-gu, Seoul 01812, KR
Inventors: LEE, Kee-Ho; KR
KIM, Sungsub; KR
KIM, Yeon-Soo; KR
PARK, Eun-Ran; KR
SHIN, Hyun Jin; KR
LEE, Eun-Ju; KR
HAM, Yong-Ho; KR
KIM, Sang Bum; KR
PARK, Sun-Hoo; KR
HAN, Chul-Ju; KR
HONG, Sung Hee; KR
KIM, Yang Hyun; KR
KIM, Jung Min; KR
KIM, Mi Yeun; KR
KANG, Moonkyoung; KR
SONG, Eun Yeong; KR
SONG, Jie Young; KR
Agent: SON, Min; KR
Priority Data:
10-2015-014166708.10.2015KR
Title (EN) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING INHIBITOR OF PLRG1 (PLEIOTROPIC REGULATOR 1) AS ACTIVE INGREDIENT
(FR) COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR OU TRAITER UN CANCER COMPRENANT UN INHIBITEUR DE PLRG1 (RÉGULATEUR PLÉIOTROPIQUE 1) COMME PRINCIPE ACTIF
(KO) PLRG1 (PLEIOTROPIC REGULATOR 1) 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
Abstract: front page image
(EN) The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising an inhibitor of PLRG1 (pleiotropic regulator 1) as an active ingredient, a method for treating cancer comprising a step of administering the composition to an individual, a composition for diagnosing cancer comprising an agent for measuring an expression level of PLRG1, and a method for providing information for diagnosing cancer comprising a step of measuring an expression level of PLRG1, and a method for screening an agent for preventing or treating cancer. PLRG1 (pleiotropic regulator 1) is overexpressed in cancer cells, and when an expression of PLRG1 is inhibited, a cancer cell-specific cell death can be induced. Thus, the inhibitor of PLRG1 of the present invention has an excellent effect as an anticancer agent without side effects, and also can be used to diagnose cancer and screen anticancer agents by measuring an expression level of PLRG1.
(FR) La présente invention concerne une composition pharmaceutique pour prévenir ou traiter un cancer comprenant un inhibiteur de PLRG1 (régulateur pléiotropique 1) comme principe actif, un procédé pour traiter un cancer comprenant une étape consistant à administrer la composition à un individu, une composition pour le diagnostic de cancer comprenant un agent pour mesurer un niveau d'expression de PLRG1, et un procédé pour fournir des informations pour le diagnostic de cancer comprenant une étape consistant à mesurer un niveau d'expression de PLRG1, et un procédé pour cribler un agent pour prévenir ou traiter un cancer. PLRG1 (régulateur pléiotropique 1) est surexprimé dans des cellules cancéreuses et, lorsqu'une expression de PLRG1 est inhibée, une mort cellulaire spécifique à une cellule cancéreuse peut être induite. Ainsi, l'inhibiteur de PLRG1 de la présente invention a un excellent effet comme agent anticancéreux sans effet secondaire, et peut également être utilisé pour diagnostiquer un cancer et cribler des agents anticancéreux en mesurant un niveau d'expression de PLRG1.
(KO) 본 발명은 PLRG1 (pleiotropic regulator 1) 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물, 상기 조성물을 개체에 투여하는 단계를 포함하는 암의 치료 방법, PLRG1의 발현 수준을 측정하는 제제를 포함하는 암 진단용 조성물, 및 PLRG1의 발현 수준을 측정하는 단계를 포함하는 암 진단을 위한 정보를 제공하는 방법 및 암의 예방 또는 치료용 제제의 스크리닝 방법에 관한 것이다. PLRG1 (pleiotropic regulator 1)은 암 세포에서 과발현되고, 이의 발현을 억제하는 경우 암 세포 특이적으로 세포 사멸을 유도할 수 있다. 이에, 본 발명의 PLRG1 억제제는 부작용 없이 항암제로 우수한 효과가 있으며, 또한 PLRG1 발현 수준을 측정함으로써 암 진단 및 항암제 스크리닝 등에 활용할 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)